How amenable is type 2 diabetes treatment for precision diabetology? A meta-regression of glycaemic control data from 174 randomised trials
Primary result · Variability of HbA1c after treatment (log(SD))Result — go to the resultAdjusted difference in log(SD) 0.037 95% CI 0.004–0.069Authors' conclusion
The potential of the precision medicine approach in the treatment of type 2 diabetes is modest at best, at least with regard to an improvement in glycaemic control. Our finding of a larger variability after treatment with GLP-1 receptor agonists in individuals with poor glycaemic control should be replicated and/or validated with other clinical outcomes and with different study designs.
Study context
- Population
- Participants with T2D in placebo-controlled RCTs
- Participants
- 86,940 participants174 RCTs
- Comparison
- Verum vs placebo arms
- Verumn = 272
- Placebon = 178reference
- Primary endpoint
- Variability of glycaemic control (HbA1c) after treatment: difference in log(SD) between verum and placebo arms
Primary result
Variability of HbA1c after treatment (log(SD))
Adjusted difference in log(SD)
0.037
95% CI 0.004–0.069
Verumvs Placebo
adjusted difference in log(SD) 0.037 (95% CI 0.004–0.069)
As reported in the abstract
Further findings
Predictors of increased variability
- Drug class was a potentially relevant predictor; GLP-1 RA yielded the largest differences in log(SD)
Original publication
How amenable is type 2 diabetes treatment for precision diabetology? A meta-regression of glycaemic control data from 174 randomised trials. Diabetologia. Published 20 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →